Study of How Doctors Use Electronic Patient Reports to Adjust Treatments for Gout, Rheumatoid Arthritis, Sjogrens Syndrome, or Lupus

What this Trial Is About

Inflammatory rheumatic diseases such as gout, rheumatoid arthritis, Sjogrens syndrome, and systemic lupus erythematosus affect about 1% of the population and often require treatment based on disease activity, safety, and patient characteristics including comorbidities. This research aims to assess how using electronic patient-reported outcomes ePROs to provide physicians with direct patient health feedback influences therapeutic decisions. The study hypothesizes that better physician access to patient health data will encourage a treat-to-target approach with more frequent treatment adjustments. Participants are divided into groups based on whether their physician uses an electronic platform to access the patients ePRO data or not. The study tracks therapeutic management over time with no direct intervention but by monitoring the physicians use of patient-reported information. The platform notifies investigators when a patient completes a form but does not interpret the data or generate alerts. During the study, patients will provide regular health feedback through ePROs while researchers monitor treatment adjustments over 12 months as the primary outcome. Secondary outcomes include treatment changes at 6 and 24 months, flare frequency, disease activity measured by RAPID 3 questionnaires, health status via HAQ scores, physical activity levels, patient-physician interaction efficacy, and platform login frequency by both patients and physicians. The study involves ongoing assessments and data collection to understand how ePRO usage affects patient care over the course of up to 24 months.

Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments